ERBB2 and breast carcinoma: Our data suggest that elevated cMLC-1 (79 patients consisting of ~50% each of HER2- and HER2+) vs. 46 normal donors, p=0,0006) may be a potential candidate as a biomarker for initial and/or combinational screening of women under 40 who are at high risk for breast cancer (Figure 2).